Article révisé par les pairs
Titre:
  • Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
Auteur:Van Laethem, Jean-Luc; Hammel, Pascal; Mornex, Françoise; Azria, David; Van Tienhoven, Geertjan; Vergauwe, Philippe; Peeters, Marc; Polus, Marc; Praet, Michel; Mauer, Murielle; Collette, Laurence; Budach, Volker; Lutz, Manfred B.; Van Cutsem, Eric; Haustermans, Karin
Informations sur la publication:Journal of clinical oncology, 28, 29, page (4450-4456)
Statut de publication:Publié, 2010-10
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged
Antimetabolites, Antineoplastic -- adverse effects -- therapeutic use
Chemotherapy, Adjuvant
Combined Modality Therapy
Deoxycytidine -- adverse effects -- analogs & derivatives -- therapeutic use
Diarrhea -- chemically induced
Drug Administration Schedule
Fatigue -- chemically induced
Feasibility Studies
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Nausea -- chemically induced
Pancreatic Neoplasms -- drug therapy -- radiotherapy -- surgery
Radiotherapy, Adjuvant
Treatment Outcome
Note générale:Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0732-183X
info:doi/10.1200/JCO.2010.30.3446
info:pii/JCO.2010.30.3446
info:pmid/20837948
PMC2988636

Documents en relation

DI-fusion